Evaluation of SEPP1 and Selenoprotein S Gene Polymorphisms (rs7579 and rs34713741) in Relation to Colorectal Cancer Susceptibility in Subset of Iranian Population: A Case–control Study

Amini, Guilda; Salehi, Rasoul; Moshtaghi, Ali Asghar; Kazemi, Mohammad; Behjati, Mohaddeseh; Khosravi, Sharifeh

Evaluation of SEPP1 and Selenoprotein S Gene Polymorphisms (rs7579 and rs34713741) in Relation to Colorectal Cancer Susceptibility in Subset of Iranian Population: A Case–control Study

Document Type : Original Article

Authors

¹ Department of Biochemistry, Falavarjan Islamic Azad University, Falavarjan; Depatment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Depatment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Biochemistry, Falavarjan Islamic Azad University, Falavarjan, Iran

⁴ Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Colorectal cancer (CRC) is rated as the second cause of cancer death worldwide. Selenium (Se) has antioxidant activity and antitumor effect, especially in colon cancer. This important role occurs through selenoproteins. Low Se intake or low plasma Se and selenoproteins concentrations are associated with higher risk of CRC. rs7579 polymorphism in 3' untranslated region of the SEPP1 gene can effect on selenocysteine incorporation during protein synthesis and also effect on microRNA -messengerRNA interaction and sequentially change in SEPP1 expression. rs34713741 polymorphism as a promoter variant in selenoprotein S (SELS) gene can effect on SElS expression and finally lead to increased CRC risk. Methods: A case-control study using 60 CRC patients and 74 noncancerous counterparts were undertaken in order to determine rs7579 and rs34713741 genotypes using real-time polymerase chain reaction high-resolution melting method. Results: We found an association of borderline statistical significance between allele A for rs7579 in SEPP 1 and CRC risk (adjusted odds ratio = 1.63; confidential interval = 0.99-2.07; P = 0.05). The frequency of genotypes rs34713741 of the mentioned polymorphisms was not significantly different between case and control groups (P = 0.23 and P = 0.93, respectively). Conclusions: The results suggest that these polymorphisms probably has not a substantial role in Iranian CRC risk and is not a serious potential factor in risk assessment of mentioned disease among Iranians.

Keywords

References

1.	Alwan A. Global status report on noncommunicable diseases 2010. World Health Organization; 2011.
2.	Etemadi A, Sadjadi A, Semnani S, Nouraie SM, Khademi H, Bahadori M, et al. Cancer registry in Iran: A brief overview. Arch Iran Med 2008;11:577-80.
3.	Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr 2005;135:343-7.
4.	Russo MW, Murray SC, Wurzelmann JI, Woosley JT, Sandler RS. Plasma selenium levels and the risk of colorectal adenomas. Nutr Cancer 1997;28:125-9.
5.	Steinbrecher A, Méplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, et al. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010;19:2958-68.
6.	Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mörk H, Scheurlen M, et al. Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer 2004;48:6-14.
7.	Cooper ML, Adami HO, Grönberg H, Wiklund F, Green FR, Rayman MP, et al. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008;68:10171-7.
8.	Scheurig AC, Thorand B, Fischer B, Heier M, Koenig W. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: Results of the MONICA/KORA augsburg study. Eur J Clin Nutr 2008;62:127-37.
9.	Duntas LH. Selenium and inflammation: Underlying anti-inflammatory mechanisms. Horm Metab Res 2009;41:443-7.
10.	Bellinger FP, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009;422:11-22.
11.	Méplan C, Crosley LK, Nicol F, Beckett GJ, Howie AF, Hill KE, et al. Genetic polymorphisms in the human selenoprotein Pgene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J 2007;21:3063-74.
12.	Sutherland A, Kim DH, Relton C, Ahn YO, Hesketh J. Polymorphisms in the selenoprotein S and 15-kDa selenoprotein genes are associated with altered susceptibility to colorectal cancer. Genes Nutr 2010;5:215-23.
13.	Brown KM, Arthur JR. Selenium, selenoproteins and human health: A review. Public Health Nutr 2001;4:593-9.
14.	Hill KE, Zhou J, McMahan WJ, Motley AK, Atkins JF, Gesteland RF, et al. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 2003;278:13640-6.
15.	Jablonska E, Raimondi S, Gromadzinska J, Reszka E, Wieczorek E, Krol MB, et al. DNA damage and oxidative stress response to selenium yeast in the non-smoking individuals: A short-term supplementation trial with respect to GPX1 and SEPP1 polymorphism. Eur J Nutr 2016;55:2469-84.
16.	Bosschaerts T, Guilliams M, Noel W, Hérin M, Burk RF, Hill KE, et al. Alternatively activated myeloid cells limit pathogenicity associated with african trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol 2008;180:6168-75.
17.	Burk RF, Early DS, Hill KE, Palmer IS, Boeglin ME. Plasma selenium in patients with cirrhosis. Hepatology 1998;27:794-8.
18.	Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, Tsujikawa T, et al. Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition 2005;21:574-9.
19.	Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, et al. Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 2005;37:1234-41.
20.	Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004;429:841-7.
21.	Labunskyy VM, Yoo MH, Hatfield DL, Gladyshev VN. Sep15, a thioredoxin-like selenoprotein, is involved in the unfolded protein response and differentially regulated by adaptive and acute ER stresses. Biochemistry 2009;48:8458-65.
22.	Cardoso BR, Busse AL, Hare DJ, Cominetti C, Horst MA, McColl G, et al. Pro198Leu polymorphism affects the selenium status and GPx activity in response to Brazil nut intake. Food Funct 2016;7:825-33.
23.	Simonian M, Mosallayi M, Miraghajani M, Feizi A, Khosravi S, Salehi AR, et al. Single nucleotide polymorphism rs696 in miR449a binding site of NFKBIA gene is correlated with risk of colorectal cancer. Gastroenterol Hepatol Bed Bench 2018;11:48-53.
24.	Mosallaei M, Simonian M, Ahangari F, Miraghajani M, Mortazavi D, Salehi AR, et al. Single nucleotide polymorphism rs4648298 in miRNAs hsa-miR21 and hsa-miR590 binding site of COX gene is a strong colorectal cancer determinant. J Gastrointest Oncol 2018;9:448-57.
25.	Geybels MS, van den Brandt PA, Schouten LJ, van Schooten FJ, van Breda SG, Rayman MP, et al. Selenoprotein gene variants, toenail selenium levels, and risk for advanced prostate cancer. J Natl Cancer Inst 2014;106:dju003.
26.	Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, et al. Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis 2010;31:1074-9.
27.	Mao H, Cui R, Wang X. Association analysis of selenoprotein S polymorphisms in chinese han with susceptibility to gastric cancer. Int J Clin Exp Med 2015;8:10993-9.
28.	Roberts-Thomson IC, Butler WJ. Polymorphism and gastric cancer. J Gastroenterol Hepatol 2005;20:793-4.
29.	Méplan C, Hesketh J. The influence of selenium and selenoprotein gene variants on colorectal cancer risk. Mutagenesis 2012;27:177-86.
30.	Hesketh J, Méplan C. Transcriptomics and functional genetic polymorphisms as biomarkers of micronutrient function: focus on selenium as an exemplar. Proceedings of the Nutrition Society. 2011;70(3):365-73.
31.	Curti ML, Jacob P, Borges MC, Rogero MM, Ferreira SR. Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: Implications for a nutrigenetic approach. J Obes 2011;2011:497401.
32.	McConnell BB, Yang VW. The role of inflammation in the pathogenesis of colorectal cancer. Curr Colorectal Cancer Rep 2009;5:69-74.
33.	Méplan C, Hesketh J, editors. Genetic polymorphisms in selenoprotein Pgene affect colorectal, prostate and breast cancer risk. Proceedings of the Nutrition Society. Shaftesbury RD, CB2 8RU Cambridge, England: Cambridge Univ Press Edinburgh Bldg; 2013.
34.	Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: Functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002;62:5325-35.
35.	Méplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers JC, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 2009;11:2631-40.
36.	Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, Chanock SJ, et al. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2008;17:1144-54.
37.	Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, et al. Selenoprotein Pgenetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate 2013;73:700-5.
38.	Méplan C, Dragsted LO, Ravn-Haren G, Tjønneland A, Vogel U, Hesketh J, et al. Association between polymorphisms in glutathione peroxidase and selenoprotein Pgenes, glutathione peroxidase activity, HRT use and breast cancer risk. PLoS One 2013;8:e73316.

Advanced Biomedical Research